ClinConnect ClinConnect Logo
Search / Trial NCT03942081

Diabetic Foot Ulcer Imaging- Study 2

Launched by LINNEA POLGREEN · May 7, 2019

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

The Diabetic Foot Ulcer Imaging- Study 2 is a clinical trial focused on understanding foot ulcers in people with diabetes. If you have been diagnosed with either Type 1 or Type 2 diabetes and currently have a foot ulcer, you might be eligible to participate. The study is open to individuals between 76 and 365 years old who are receiving care at specific clinics associated with the University of Iowa Hospitals and Clinics.

During the trial, you will only need to attend one appointment. At this appointment, the research team will measure the size of your foot ulcer and take several pictures using both a smartphone and a thermal camera to help with their analysis. They will also gather some demographic information from your medical records. This study is important because it aims to improve how foot ulcers are treated and understood, helping future patients manage this condition better.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Diagnosed with Type 1 or Type 2 Diabetes
  • Has a current foot lesion
  • Receiving care through University of Iowa Hospitals and Clinics (UIHC) Iowa River Landing Diabetes Clinic, UIHC Internal Medicine Clinic, or UIHC Orthopedic Clinic.
  • Exclusion Criteria:
  • Cognitive impairment that prevents consent
  • Lack of fluency in speaking or understanding English
  • Known aversion to research studies

About Linnea Polgreen

Linnea Polgreen is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes. With a commitment to innovation and excellence, Linnea Polgreen oversees the design, implementation, and management of clinical trials across various therapeutic areas. The organization collaborates with leading healthcare professionals and institutions to ensure rigorous adherence to regulatory standards, ethical practices, and scientific integrity. By prioritizing patient safety and data reliability, Linnea Polgreen aims to contribute significantly to the development of new therapies and enhance the understanding of complex medical conditions.

Locations

Iowa City, Iowa, United States

Patients applied

0 patients applied

Trial Officials

Linnea Polgreen, PhD

Principal Investigator

University of Iowa

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials